Received Jun 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 1 | — | — |
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
No additional AE; HCP called to report inadvertent administration of ROTATEQ and VAXELIS after a temperature excursion that occurred on 07MAY2025. ROTATEQ and VAXELIS were administered to a patient on 21MAY2025. Limited demographics provided. HCP originally called on; This spontaneous report was received from a Nurse Practitioner and refers to a 6-month-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 07-May-2025, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (VAXELIS), dose number 1, (lot # and expiration date were not reported), and Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), dose number 1, (lot # and expiration date were not reported) had a temperature excursion of 1.4 degrees Celsius for 18 minutes and was administered to the patient on 21-May-2025 (Product storage error). No adverse event was reported.; Reporter's Comments: